Henderson Molly
Known title: CFO and CBOCIK: 0001363812
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
UroGen Pharma highlighted as emerging GARP stock. UroGen Pharma is being discussed as an emerging GARP stock, indicating growing interest from analysts. The average target price of $60.00, with a range of $48.00 to $75.00, suggests potential upside from its current level. The stock trades near its 12‑touch support at $40.15 and has a moderate RSI of 35.3, indicating it is not overbought. These factors may influence how investors view its future performance.
Transaction History
| PHAT | ▼ Sell | Open Market | 3,678 | $17K | 4/7/2025 | View on chart |
| PHAT | ▲ Buy | Grant | 72,000 | $0 | 2/27/2025 | View on chart |
| PHAT | ▼ Sell | Open Market | 6,583 | $43K | 1/21/2025 | View on chart |
| PHAT | ▼ Sell | Open Market | 1,291 | $10K | 12/19/2024 | View on chart |
| PHAT | ▼ Sell | Open Market | 4,325 | $51K | 7/15/2024 | View on chart |
| PHAT | ▲ Buy | Grant | 7,500 | $0 | 5/31/2024 | View on chart |
| PHAT | ▼ Sell | Open Market | 3,435 | $38K | 4/8/2024 | View on chart |
| PHAT | ▼ Sell | Open Market | 6,307 | $49K | 1/19/2024 | View on chart |
| PHAT | ▼ Sell | Open Market | 2,127 | $15K | 11/20/2023 | View on chart |
| PHAT | ▲ Buy | Grant | 22,500 | $0 | 11/1/2023 | View on chart |
| PHAT | ▼ Sell | Open Market | 811 | $6K | 11/1/2023 | View on chart |
| PHAT | ▼ Sell | Open Market | 11,681 | $105K | 11/1/2023 | View on chart |
| PHAT | ▲ Buy | Grant | 25,000 | $25K | 7/14/2023 | View on chart |
| PHAT | ▼ Sell | Open Market | 1,960 | $22K | 6/2/2023 | View on chart |
| PHAT | ▼ Sell | Open Market | 2,110 | $27K | 5/22/2023 | View on chart |
| PHAT | ▼ Sell | Open Market | 3,439 | $25K | 4/6/2023 | View on chart |
| PHAT | ▼ Sell | Open Market | 2,032 | $17K | 3/1/2023 | View on chart |
| PHAT | ▲ Buy | Grant | 33,000 | $0 | 1/19/2023 | View on chart |
| PHAT | ▼ Sell | Open Market | 2,159 | $21K | 11/21/2022 | View on chart |
| PHAT | ▲ Buy | Grant | 7,500 | $0 | 9/1/2022 | View on chart |
| PHAT | ▲ Buy | Grant | 12,000 | $0 | 5/19/2022 | View on chart |
| PHAT | ▲ Buy | Open Market | 6,000 | — | 5/13/2022 | View on chart |
| PHAT | ▲ Buy | Grant | 20,000 | $0 | 4/5/2022 | View on chart |
| URGN | ▲ Buy | Option Exercise | 666 | — | 1/31/2022 | View on chart |
| URGN | ▼ Sell | Open Market | 331 | $3K | 1/31/2022 | View on chart |
| URGN | ▲ Buy | Option Exercise | 5,000 | — | 11/30/2021 | View on chart |
| URGN | ▼ Sell | Open Market | 2,587 | $31K | 11/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
PHAT launches Phase 3 study for VOQUEZNA in GERD
Phathom Pharmaceuticals has begun a Phase 3 trial of VOQUEZNA, a drug aimed at treating non‑erosive gastro‑esophageal reflux disease on an as‑needed basis. The study is a critical step toward regulatory approval and could expand the company’s product portfolio. The move follows earlier development phases and may influence investor perception of the company’s growth prospects.
PHAT launches Phase 3 study for VOQUEZNA in GERD. Phathom Pharmaceuticals has begun a Phase 3 trial of VOQUEZNA, a drug aimed at treating non‑erosive gastro‑esophageal reflux disease on an as‑needed basis. The study is a critical step toward regulatory approval and could expand the company’s product portfolio. The move follows earlier development phases and may influence investor perception of the company’s growth prospects.